Clinical Trial

Tang Prize in Biopharmaceutical Science Honoring Three Scientists

TAIPEI, June 19, 2024 /PRNewswire/ -- In a continuing series of laureate announcements, the Tang Prize Foundation today (June 19th) announced…

2 years ago

Cosmo’s Oral Diagnostic Drug Lumeblue(R) Receives Approval of New Drug Application in China

Dublin, Ireland--(Newsfile Corp. - June 18, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) reported that its partner…

2 years ago

BrainCheck and Alzheimer’s Association Partner to Present Live Panel Event on Advancements in Brain Health and Dementia Care

Moderated by Emmy award-winning Spectrum News 1 Anchor and National Mental Health Correspondent, Nicole Clark, Ph.D., panel to feature renowned experts…

2 years ago

Angle PLC Announces Posting of 2023 Annual Report & Notice of the AGM

GUILDFORD, SURREY / ACCESSWIRE / June 18, 2024 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with…

2 years ago

Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be…

2 years ago

Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in…

2 years ago

Elicio Therapeutics Reports Inducement Grants

BOSTON, June 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company…

2 years ago

Prenetics Announces First Quarter 2024 Financial Results

First Quarter Revenue Increased 30.2% and Gross Profit Increased 159.8% from Prior Year Quarter Confirms Strategic Pivot Targeting the U.S.…

2 years ago

Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection

– Phase 1b study will evaluate safety, pharmacokinetic and efficacy endpoints in participants with chronic hepatitis B virus infection with…

2 years ago